331 related articles for article (PubMed ID: 29848907)
1. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Abe H; Natsumeda M; Kanemaru Y; Watanabe J; Tsukamoto Y; Okada M; Yoshimura J; Oishi M; Fujii Y
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):290-295. PubMed ID: 29848907
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
3. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
[TBL] [Abstract][Full Text] [Related]
5. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
6. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
Kurdi M; Alkhotani A; Sabbagh A; Faizo E; Lary AI; Bamaga AK; Almansouri M; Hafiz B; Alsharif T; Baeesa S
Oncol Res; 2024; 32(6):1037-1045. PubMed ID: 38827324
[TBL] [Abstract][Full Text] [Related]
7. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
8.
Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
[TBL] [Abstract][Full Text] [Related]
9. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
[TBL] [Abstract][Full Text] [Related]
10. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
11. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
[TBL] [Abstract][Full Text] [Related]
12. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
14. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Oldrini B; Vaquero-Siguero N; Mu Q; Kroon P; Zhang Y; Galán-Ganga M; Bao Z; Wang Z; Liu H; Sa JK; Zhao J; Kim H; Rodriguez-Perales S; Nam DH; Verhaak RGW; Rabadan R; Jiang T; Wang J; Squatrito M
Nat Commun; 2020 Aug; 11(1):3883. PubMed ID: 32753598
[TBL] [Abstract][Full Text] [Related]
15. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
16. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
17. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
19. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol.
O'Regan CJ; Kearney H; Beausang A; Farrell MA; Brett FM; Cryan JB; Loftus TE; Buckley PG
J Neurooncol; 2018 Apr; 137(2):233-240. PubMed ID: 29264834
[TBL] [Abstract][Full Text] [Related]
20. The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
Kinashi Y; Ikawa T; Takahashi S
Appl Radiat Isot; 2020 Sep; 163():109204. PubMed ID: 32561044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
